Tasly Holding Group

Founded in 1994, Tasly Group has achieved leapfrog development over the past three decades and has now become a high-tech enterprise group oriented towards internationalization, with the major health industry as its main line, and the two major industrial systems of biomedicine and digital-intelligent health advancing collaboratively. It ranks among the Top 500 Chinese Manufacturing Enterprises, the Top 500 Chinese Private Enterprises, and the Top 100 Chinese Large Enterprises for Innovation.
Tasly's biomedical industry system actively integrates its corporate development strategy and innovative achievements into the national development landscape, and actively responds to the national 'Belt and Road' initiative. It has built a grand biomedical industry pattern with the coordinated development of modern traditional Chinese medicine, biopharmaceuticals, and chemical drugs, and has meticulously created a new drug precision R&D platform, a new drug innovative technology platform, a 4.0 intelligent manufacturing platform, and a smart service platform, all led by artificial intelligence and international standards. It has successively been awarded honors such as 'National Key Laboratory for Key Technologies of Innovative Traditional Chinese Medicine' and 'National-Local Joint Engineering Laboratory for Advanced Manufacturing Technology of Traditional Chinese Medicine', and has won the fourth 'China Industrial Award' and other accolades. In 2024, Tasly and Huawei jointly launched the 'Digital Intelligent Herbal' large model, committed to creating a new paradigm for 'digital-intelligent traditional Chinese medicine' in terms of resources, R&D, manufacturing, supply, clinical application, and consumer cognition, actively promoting the widespread application of diverse ecological scenarios, thereby driving the entire traditional Chinese medicine industry chain to achieve transformative upgrading, effectively advancing the modernization and internationalization of traditional Chinese medicine, and striding forward towards the grand vision of digital-intelligent traditional Chinese medicine characterized by precision in medication, mechanization in production, and precision in efficacy.
Tasly's digital-intelligent health industry system, taking pharmaceutical core competitiveness as its origin and resource-based industries as breakthroughs, promotes the digital-intelligent upgrading of traditional industries through empowering innovation. It owns several well-known brands and industrial companies. Among them, Guizhou Guotai Digital Intelligent Distillery Group Co., Ltd., as the second largest liquor-making enterprise in Maotai Town designated by the government, deeply practices the new development philosophy, firmly follows the path of new industrialization, adheres to the principle of 'not being rigidly bound by tradition, yet never departing from its essence in scientific innovation', and continuously promotes the transformation and upgrading from traditional brewing to intelligent brewing. It has successively won numerous honors granted by relevant national ministries and commissions, such as 'Listed Unit of Intelligent Manufacturing Demonstration Factory' and 'Intelligent Manufacturing System Solution Leader Project'. The Guotai brand has been repeatedly selected for CCTV's 'Brand Powering the Nation Project' and 'National Craftsmanship Brand', and in 2024, its brand value reached 224.436 billion yuan, continuously ranking tenth among Chinese liquor brands and third among Guizhou liquor brands, successfully entering the ranks of China's first-tier liquor enterprises and mainstream sauce-flavored liquor brands. It has consolidated its brand and industry position as 'Great Sauce-flavor Country · Guotai Leading', and is making every effort to contribute more significantly to the Chinese liquor industry, national brands, and economic and social development.